Synthesis and antihyperglycemic activity of novel N-acyl-2-arylethylamines and N-acyl-3-coumarylamines.
A series of novel N-acyl-2-arylethylamines and N-acyl-3-coumarylamines were synthesized and evaluated for their antihyperglycemic activity. Compounds 3g and 6d exhibited lowering of postprandial plasma glucose by 30.7%, 23.3% in SLM and 25.6%, 25.4% in STZ models respectively which is significant compared to metformin and glybenclamide. Other compounds exhibited moderate to good activity ranging from 19.5% to 32.8% in SLM and 3.26% to 25.4% in STZ models.
Dwivedi
Atma P
AP
Medicinal and Process Chemistry Division, Central Drug Research Institute, M.G. Marg, P B No. 173, Lucknow 226001, India.
Kumar
Shailesh
S
Varshney
Vandana
V
Singh
Amar B
AB
Srivastava
Arvind K
AK
Sahu
Devi P
DP
D000215:Acylation; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism*; D003373:Coumaric Acids / Q000138:chemical synthesis / Q000378:metabolism / Q000627:therapeutic use*; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D005021:Ethylamines / Q000138:chemical synthesis / Q000378:metabolism / Q000627:therapeutic use*; D006943:Hyperglycemia / Q000188:drug therapy* / Q000473:pathology; D007004:Hypoglycemic Agents / Q000138:chemical synthesis / Q000378:metabolism / Q000627:therapeutic use*; D008297:Male; D008956:Models, Chemical; D051381:Rats; D017207:Rats, Sprague-Dawley; D013329:Structure-Activity Relationship
D001786:Blood Glucose; D003373:Coumaric Acids; D005021:Ethylamines; D007004:Hypoglycemic Agents